Gene
ERCC1
ERCC1 is a gene biomarker in the evidence tier "Cancer actionable (CGI)". This page lists evidence by type: Assay-provider ledger (27), Actionable biomarkers (5), Trial mentions (18), and 6 more evidence types, each linked to its source.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section (log scale)
1 more section with rows · 3 sections measured, none recorded
Cancer actionable (CGI)
Evidence over time
Share of that year: what fraction of the trials and papers our biomarker dictionary matched in a year mention ERCC1. The denominator is documents that mention any gene, not every registered document, so improving the matcher moves both halves and never rewrites history. Gene named in free-text trial records. A mention, not a validated biomarker. Actionable-biomarker and target-disease-association evidence carries no date in our sources, so it is not on this chart. Publication mentions cover only papers cited by a registered clinical trial, not all of PubMed.
Trial mentions: plotted from 1990 to 2026, the years our matched corpus covers.
Publication mentions: plotted from 1990 to 2023, the years our matched corpus covers. Not plotted: 3 at the structurally incomplete recent edge.
The yearly numbers
| Year | Trial mentions | Share of that year | Publication mentions | Share of that year |
|---|---|---|---|---|
| 2026 | 0 of 8,738 | 0.00% | not measured | |
| 2025 | 0 of 8,875 | 0.00% | not measured | |
| 2024 | 0 of 8,597 | 0.00% | not measured | |
| 2023 | 0 of 8,275 | 0.00% | 4 of 11,460 | 0.03% |
| 2022 | 0 of 8,285 | 0.00% | 6 of 13,598 | 0.04% |
| 2021 | 0 of 8,692 | 0.00% | 13 of 15,045 | 0.09% |
| 2020 | 0 of 7,640 | 0.00% | 13 of 14,459 | 0.09% |
| 2019 | 0 of 7,300 | 0.00% | 14 of 12,159 | 0.12% |
| 2018 | 0 of 6,927 | 0.00% | 12 of 11,854 | 0.10% |
| 2017 | 1 of 6,558 | 0.02% | 9 of 11,595 | 0.08% |
Showing 10 of 37 years.
Assay-provider ledger (27)
Shown in this order: most recent publication first.
| Company | Provider class | Validation | Papers | Most recent publication |
|---|---|---|---|---|
| QIAGEN | Reagent supplier | Clinical validationAnalytical validation | 2 | May 17, 2021 |
| QIAGEN Hannover GmbH | Diagnostic provider | Clinical validationAnalytical validation | 1 | April 11, 2017 |
| Takeda | Pharma or other | Analytical validation | 1 | December 01, 2016 |
| Affymetrix | Reagent supplier | Clinical validation | 2 | August 02, 2016 |
| Frederick National Laboratory for Cancer Research | Not a company | Clinical validationAnalytical validation | 1 | August 01, 2016 |
Showing 5 of 27 assay-provider companies.
Actionable biomarkers (5)
Shown in this order: fixed catalogue order, not ranked.
| Alteration | Drug | Response | Disease | Source |
|---|---|---|---|---|
| ERCC1 oncogenic mutation | CISPLATIN | response-associated | lung carcinoma | Cancer Genome Interpreter |
| ERCC1 deletion | Parp Inhibitors | response-associated | lung carcinoma | Cancer Genome Interpreter |
| ERCC1 oncogenic mutation | Parp Inhibitors | response-associated | lung carcinoma | Cancer Genome Interpreter |
| ERCC1 deletion | CISPLATIN | response-associated | lung carcinoma | Cancer Genome Interpreter |
| ERCC1 overexpression | CISPLATIN | responsive | No disease recorded | Cancer Genome Interpreter |
Trial mentions (18)
Shown in this order: fixed catalogue order, not by date.
| Trial | Source |
|---|---|
| NCT01003964 | Trial eligibility (AACT) |
| NCT00801736 | Trial eligibility (AACT) |
| NCT01386385 | Trial eligibility (AACT) |
| NCT00728000 | Trial eligibility (AACT) |
| NCT01074398 | Trial eligibility (AACT) |
Showing 5 of 18 trial mentions.
Target-disease associations (214)
Shown in this order: fixed catalogue order, not ranked.
| Disease | Therapeutic area | Source |
|---|---|---|
| Anxiety | phenotype | Literature (Europe PMC) |
| Autosomal dominant polycystic kidney disease | genetic, familial or congenital disease | Mouse knockout (IMPC) |
| Autosomal recessive spastic paraplegia type 26 | genetic, familial or congenital disease | Mouse knockout (IMPC) |
| COFS syndrome | disorder of visual system | Variant curation (ClinVar / EVA) |
| COFS syndrome | disorder of visual system | gene2phenotype |
Showing 5 of 214 associations.
Vendor sourcing (50)
Shown in this order: alphabetical by organization.
| Organization | Role | Tier | Evidence | Citation |
|---|---|---|---|---|
| Albert Einstein College of Medicine | Trial sponsor | Mentioned in trial textTrial free-text mention | ERCC1 | View trial NCT00846482 |
| Ambry Genetics (United States) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | The c.223A>T (p.T75S) alteration is located in exon 2 (coding exon 2) of the ERCC1 gene. This alteration results from a A to T substitution at nucleotide pos... | View ClinVar record SCV003552018.2 |
| Aventis Pharmaceuticals | Trial collaborator | Mentioned in trial textTrial free-text mention | ERCC1 | View trial NCT00215930 |
| Cancer Research UK | Trial collaborator | Named in trial inclusion criteriaTrial eligibility criteria | 1. Histological confirmation of non-squamous NSCLC 2. Have a tissue biopsy available for sending to the central laboratory to determine ERCC1 status 3. Pre... | View trial NCT00801736 |
| Cancer Research UK | Trial collaborator | Mentioned in trial textTrial free-text mention | ERCC1 | View trial NCT00801736 |
Showing 5 of 50 sourcing records.
Trial-cited literature (188)
Shown in this order: newest first, then most cited.
| Publication | Journal | Year | Citations |
|---|---|---|---|
| Immunotherapy and senolytics in head and neck squamous cell carcinoma: phase 2 trial results. | Nature medicine | 2025 | 14 |
| STK11/LKB1 alterations worsen the poor prognosis of KRAS mutated early-stage non-squamous non-small cell lung carcinoma, results based on the phase 2 IFCT TASTE trial. | Lung cancer (Amsterdam, Netherlands) | 2024 | 9 |
| A Randomized Phase III Study of Arfolitixorin versus Leucovorin with 5-Fluorouracil, Oxaliplatin, and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer: The AGENT Trial. | Cancer research communications | 2024 | 6 |
| Updates on global epidemiology, risk and prognostic factors of gastric cancer. | World journal of gastroenterology | 2023 | 394 |
| Biomarkers in Cancer Detection, Diagnosis, and Prognosis. | Sensors (Basel, Switzerland) | 2023 | 222 |
Showing 5 of 188 papers.
Protein variant mentions (4)
Shown in this order: alphabetical by variant.
| Variant | Distinct papers | Year range | Sample papers |
|---|---|---|---|
| p.A64V | 1 | 2015 | PMID 25741868 |
| p.E62* | 1 | 2015 | PMID 25741868 |
| p.R156W | 1 | 2015 | PMID 25741868 |
| p.S267P | 1 | 2015 | PMID 25741868 |
Literature-extracted relations (106)
Shown in this order: chemicals, then diseases.
| Related entity | Kind | Source relation label | Paper | Year |
|---|---|---|---|---|
| CISPLATIN | Chemical | negative_correlate |
The DNA damage response network in the treatment of head and neck squamous cell carcinoma. | 2021 |
| CISPLATIN | Chemical | associate |
Impact of ERCC1 gene polymorphisms on response to cisplatin based therapy in oral squamous cell carcinoma (OSCC) patients. | 2020 |
| Platinum | Chemical | associate |
Impact of ERCC1 gene polymorphisms on response to cisplatin based therapy in oral squamous cell carcinoma (OSCC) patients. | 2020 |
| OXALIPLATIN | Chemical | positive_correlate |
Excision repair cross-complementing group-1 (ERCC1) induction kinetics and polymorphism are markers of inferior outcome in patients with colorectal cancer treated with oxaliplatin. | 2019 |
| Platinum | Chemical | associate |
A Pilot Trial of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Ductal Adenocarcinoma. | 2019 |
Showing 5 of 106 relation assertions.
Organizations publishing (205)
Shown in this order: most papers first.
| Organization | Type | Papers | Years |
|---|---|---|---|
| Government of the United States of America | Government | 9 | 2010 to 2022 |
| Memorial Sloan Kettering Cancer Center | Hospital | 6 | 2011 to 2020 |
| McLaren Health Care | Hospital | 5 | 2009 to 2019 |
| Dana-Farber Cancer Institute | Other | 4 | 2014 to 2025 |
| The University of Texas System | Academic | 4 | 2011 to 2020 |
Showing 5 of 205 organizations.
Where ERCC1 appears
- cancer or benign tumor
- cardiovascular disease
- disorder of visual system
- endocrine system disease
- gastrointestinal disease
- genetic, familial or congenital disease
- hematologic disease
- immune system disease
- measurement
- nervous system disease
- nutritional or metabolic disease
- phenotype
208 diseases touched.
Not on this page
Checked, with nothing recorded for this biomarker: fda companion diagnostic assertions, fda biomarker qualification projects, and human sample screening reference.